Ischemic Cerebrovascular Accident Clinical Trial
— COMPASSOfficial title:
COMPASS Trial: a Direct Aspiration First Pass Technique
Verified date | February 2018 |
Source | Medical University of South Carolina |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Intravenous (IV) tissue plasminogen activator (tPA) administration has been shown to be safe and effective for treatment of AIS within 3 hours of symptom onset, and newer evidence has shown potential benefit out to 4.5 hours. Mechanical thrombectomy for AIS patients has been shown in clinical trials to be safe up to 8 hours after symptom onset. Recent trials utilizing advanced imaging to identify patients with large vessel occlusions amenable to intra-arterial thrombectomy (IAT) have shown superiority endovascular therapy over medical therapy to result in improved patient functional outcomes. Pilot data utilizing the ADAPT approach has shown superior technical results with similar functional outcomes while lowering procedure time and device costs versus traditional stent retriever as a first line therapy approaches
Status | Completed |
Enrollment | 250 |
Est. completion date | February 2018 |
Est. primary completion date | July 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Age 18 and older (i.e., candidates must have had their 18th birthday) 2. NIHSS =8 at the time of neuroimaging 3. Presenting or persistent symptoms within 6 hours of when groin puncture can be obtained 4. Neuroimaging demonstrates large vessel proximal occlusion (distal ICA through MCA bifurcation) 5. The operator feels that the stroke can be appropriately treated with traditional endovascular approaches (the ADAPT approach or conventional first-line stent retriever approach) 6. Pre-event Modified Rankin Scale score 0-1 7. Non-contrast CT/CTA for trial eligibility performed or repeated at treating ADAPT stroke center. 8. Consenting requirements met according to local IRB Exclusion Criteria: 1. Patient is more than 6-hours from symptom onset 2. Rapidly improving neurologic examination 3. Absence of large vessel occlusion on non-invasive imaging 4. Presence of an existing or pre-existing large territory infarction 5. Known or suspected pre-existing (chronic) large vessel occlusion in the symptomatic territory 6. Absent femoral pulses 7. Excessive vascular access tortuosity that will likely result in unstable access platform. 8. Pregnancy; if a woman is of child-bearing potential a urine or serum beta HCG test is positive. 9. Severe contrast allergy or absolute contraindication to iodinated contrast. 10. Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic. 11. Patient has a severe or fatal comorbidities that will likely prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient. Head CT or MRI Scan Exclusion Criteria - Presence of blood on imaging (subarachnoid hemorrhage (SAH)), intracerebral hemorrhage (ICH), etc.) - High density lesion consistent with hemorrhage of any degree - Significant mass effect with midline shift - Core infarct lesion volume >50 cc. - Large (more than 1/3 of the middle cerebral artery) regions of clear hypodensity on the baseline CT scan or ASPECTS of < 7; Sulcal effacement and/or loss of grey-white differentiation alone are not contraindications for treatment. |
Country | Name | City | State |
---|---|---|---|
United States | Medical University of South Carolina | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina | Icahn School of Medicine at Mount Sinai |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 90-day global disability assess via the modified Rankin Scale score (mRS) | The primary objective is to show that AIS patients, with appropriate image selection, treated with ADAPT mechanical thrombectomy approach within 6 hours of symptom onset do not have inferior clinical outcomes to those treated with a first-line stent retriever approach with 90-day global disability assessed via the modified Rankin Scale score (mRS), analyzed using success criteria as mRS 0 to 2. | 2 years | |
Secondary | Cost effectiveness of ADAPT approach | Demonstrate that the ADAPT approach is technically a superior and more cost effective approach than primary stent retriever use in the treatment of AIS. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02002390 -
Efficacy and Safety of FTY720 for Acute Stroke
|
Phase 2 | |
Completed |
NCT02523261 -
Interest of Direct Aspiration First Pass Technique (ADAPT) for Thrombectomy Revascularisation of Large Vessel Occlusion in Acute Ischaemic Stroke
|
N/A | |
Withdrawn |
NCT01985100 -
The Use of Hyperbaric Oxygen to Increase the Blood Supply in the Injured, But Still Alive Tissue, Around an Old Stroke
|
N/A | |
Completed |
NCT01934374 -
Long-Term Effects of Task-Oriented Lower Extremity Strengthening Training
|
N/A | |
Completed |
NCT02452216 -
Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS
|
Early Phase 1 | |
Completed |
NCT02776540 -
Clopidogrel for Acute Ischaemia of Recent Onset
|
Phase 4 | |
Not yet recruiting |
NCT04205578 -
NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events
|
Phase 3 | |
Recruiting |
NCT02900521 -
Population-based Brest Stroke Registry
|
||
Not yet recruiting |
NCT02347358 -
Mechanical Opening Device Implantation Following Intravenous r-tPA for Recanalization in Acute Ischemic Stroke
|
Phase 2 | |
Not yet recruiting |
NCT04763161 -
Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Case-control Study
|
||
Recruiting |
NCT03570060 -
Stepwise Screening for Silent Atrial Fibrillation After Stroke
|